Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): Patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial Journal Article
| Authors: | Oliveira, M.; Rugo, H. S.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Toi, M.; Jhaveri, K.; Krivorotko, P.; Loibl, S.; Morales Murillo, S.; Okera, M.; Nowecki, Z.; Park, Y. H.; Sohn, J. H.; Tokunaga, E.; Yousef, S.; Zhukova, L.; Fulford, M.; Andrews, H.; Wadsworth, I.; D’Cruz, C.; Turner, N. C.; on behalf of the CAPItello-291 study group |
| Article Title: | Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): Patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial |
| Journal Title: | Lancet Oncology |
| Volume: | 25 |
| Issue: | 9 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2024-09-01 |
| Start Page: | 1231 |
| End Page: | 1244 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(24)00373-5 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| PUBMED: | 39214106 |
| DOI/URL: | |
| Notes: | Source: CINAHL Plus with Full Text |
